He said no worries the offering was heavily subscribed. Told him I don't want any shares at $39.
I am new so don't be too harsh on me if I am repeating what has already been discussed here but find the recent developments discussed in the prospectus very interesting:
On October 1, 2015, we announced additional clinical efficacy and safety data from the Company’s Phase IIb program of eteplirsen in patients with Duchenne muscular dystrophy (DMD). The data demonstrated that eteplirsen provided a statistically significant advantage of 151 meters in the ability of study participants to walk at three years, compared with external controls. Further, the fourth biopsy data confirmed the mechanism of action of eteplirsen, demonstrating exon skipping in all patients and dystrophin production in nearly all patients. New results from Sarepta’s safety database, which includes approximately 100 patients exposed to eteplirsen, showed that the eteplirsen safety profile remained consistent with prior results. Common adverse drug reactions included flushing, erythema, and mild temperature elevation. No pulmonary embolisms, hospitalizations, injection site reactions or thrombocytopenia have been observed.
The primary clinical endpoint in the NDA was the comparison of the 6MWT ITT analysis of the eteplirsen-treated group compared to an external control with similar inclusion criteria. The FDA granted eteplirsen Priority Review status and assigned a Prescription Drug User Fee Act (PDUFA) action date of February 26, 2016. On September 4, 2015, the FDA informed us that, as of that date, it planned to hold an advisory committee meeting to discuss our NDA submission. An advisory committee meeting could be held at any time prior to an FDA decision on our eteplirsen NDA and may be held in the near future. Previously, the FDA granted Rare Pediatric Disease Designation to eteplirsen, as well Orphan Drug Designation and Fast Track Status
Not sure really, I have an account at Morgan Stanley who is one of the brokers handling the secondary. He said he would put in for some shares which says he could get. Says he has other clients he wants to put in their account as well.
Only to cover when this secondary comes to market. Insider knowledge, you just can't beat it. However, this is a sign the company feels pretty good about getting the nod from the FDA.
I am betting Allergan is the acquirer.
and is growing earnings and revenue greater than 50%. The sector is much needed and will continue increase. Taking my chances here with my first purchase. Will keep adding on dips. Good luck.
Good to see my little 2 thumbs down friend is still getting up everyday to see if I made a post. LOL!! What a sad life this person must live. I will post more often to add joy in your life.